Ying Liu

Ying Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
PJPeng Jiang
Peng Jiang
CTChenfan Tian
Chenfan Tian
YZYunfeng Zheng
Yunfeng Zheng
CGChunxia Gong
Chunxia Gong
JWJinyu Wang
Jinyu Wang
YLYing Liu
Ying Liu
Objective: The purpose of this study was to investigate the correlation between stemness markers (CD44 and CD133) and clinical pathological features, and to further explore the prognostic value of co-expression of CD44 & CD133 in endometrial cancer (EC).Methods: Clinical data of stage I-III EC patients who underwent initial surgical treatment at two large tertiary medical centers from 2015 to 2020 were retrospectively collected. Cohen’s kappa coefficient was used to show the consistency of the expression between CD44 and CD133. The correlation between co-expression of CD44 & CD133 and prognosis of EC patients was explored using univariate and multivariate Cox regression analysis. Then, the prognosis models for early-stage (stage I-II) EC patients were constructed. Finally, stratified analysis was performed for EC patients in high-intermediate-risk and high-risk groups, Kaplan-Meier analysis was used to compare the survival differences between patients with and without adjuvant therapy in different co-expression states (low expression, mixed expression, high expression) of CD44 & CD133.Results: A total of 1168 EC patients were included in this study. The consistency of the expression between CD44 and CD133 was 70.5%, the kappa coefficient was 0.384. High expression of CD44 & CD133 was associated with early FIGO stage (P=0.017), superficial myometrial invasion (P=0.017), and negative lymphatic vessel space invasion (P=0.017). Cox regression analysis showed that the co-expression of CD44 & CD133 was significantly correlated with the prognosis of early-stage (stage I-II) patients (P=0.001 for recurrence and P=0.005 for death). Based on this, the nomogram models were successfully constructed to predict the prognosis of early-stage EC patients. Meanwhile, Kaplan-Meier analysis showed that patients with adjuvant therapy had a better overall prognosis than those without adjuvant therapy in high-intermediate-risk and high-risk groups. However, there was no statistically significant difference in survival between patients with and without adjuvant therapy in high expression of CD44 & CD133 group (P=0.681 for recurrence, P=0.621 for death).Conclusion: High expression of CD44 & CD133 was closely related to the adverse prognosis of early-stage EC patients. Meanwhile, patients with high expression of CD44 & CD133 may not be able to achieve significant survival benefits from adjuvant therapy.

28 August 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
JZJun Zhang
Jun Zhang
PJPeng Jiang
Peng Jiang
CGChunxia Gong
Chunxia Gong
WKWei Kong
Wei Kong
YTYuan Tu
Yuan Tu
YLYing Liu
Ying Liu
Objective: The aim of this study is to explore the consistency of P53 immunohistochemical expression between preoperative biopsy and final pathology in endometrial cancer (EC), and to predict the prognosis of patients based on the 4-tier P53 expression and classic clinicopathological parameters.Methods: The medical data of patients with stage I-III EC who received preoperative biopsy and initial surgical treatment in two medical centers was retrospectively collected. The consistency of P53 immunohistochemistry expression between preoperative biopsy and final pathology was compared using Cohen’s kappa coefficient and Sankey diagram, then 4-tier P53 expression was defined (P53wt/P53wt, P53abn/P53wt, P53wt/P53abn, and P53abn/P53abn). Univariate and multivariate Cox regression analysis was used to determine the correlation between 4-tier P53 expression and the prognosis of patients. On this basis, the nomogram models were established to predict the prognosis of patients by combining 4-layer P53 expression and classic clinicopathological parameters, then risk stratification was performed on patients.Results: A total of 1186 patients were ultimately included in this study through inclusion and exclusion criteria. Overall, the consistency of P53 expression between preoperative biopsy and final pathology was 83.8%, with a kappa coefficient of 0.624. ROC curve suggested that the AUC of 4-tier P53 expression to predict the prognosis of patients was better than AUC of P53 expression in preoperative biopsy or final pathology alone. Univariate and multivariate Cox regression analysis suggested that 4-tier P53 expression was an independent influencing factor for recurrence and death. On this basis, the nomogram models based on 4-tier P53 expression and classical clinicopathological factors were successfully established. ROC curve suggested that the AUC (AUC for recurrence and death was 0.856 and 0.838, respectively) of the models was superior to the single 4-tier P53 expression or the single classical clinicopathological parameters, which could provide a better risk stratification for patients.Conclusion: The expression of P53 immunohistochemistry had relatively good consistency between preoperative biopsy and final pathology of EC. Due to the discrepancy of P53 immunohistochemistry between preoperative biopsy and final pathology, the prognosis of patients can be better evaluated based on the 4-layer P53 expression and classic clinical pathological parameters.

7 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YZYunfeng Zheng
Yunfeng Zheng
PJPeng Jiang
Peng Jiang
YTYuan Tu
Yuan Tu
CTChenfan Tian
Chenfan Tian
JYJiaxin Yu
Jiaxin Yu
YLYing Liu
Ying Liu
This study aimed to investigate the prognostic significance of dynamic changes in the systemic inflammation response index (SIRI) for predicting endometrial cancer recurrence and to establish a predictive model for assessing patients’ recurrence-free survival (RFS). A total of 1,731 patients diagnosed with endometrial cancer who underwent surgical resection between January 2010 and December 2019 were reviewed. The analysis revealed that dynamic changes in SIRI from baseline to 3 months post-operation correlated with patient survival. Specifically, patients with a dynamic SIRI score > 0.2 had worse survival outcomes than those with a score ≤ 0.2. A nomogram incorporating dynamic SIRI showed greater accuracy in predicting RFS compared to existing risk stratification systems, allowing for stratification into high- and low-risk groups. Elevated dynamic SIRI scores indicate poor clinical outcomes in endometrial cancer, and the comprehensive prognostic model demonstrates superior predictive ability for RFS by integrating clinicopathological variables and dynamic inflammatory markers.